Zdrowie i gospodarka · 16/11/2015
FDA Withdraws Hearing Requests for Nitroglycerin Transdermal Systems
The Food and Drug Administration (FDA) has withdrawn all outstanding hearing requests for nitroglycerin drug products in transdermal systems, making it unlawful to ship these products in interstate commerce without an approved new drug application (NDA) or abbreviated new drug application (ANDA).